Genomic Precision

 A SeraCare blog focused on precision medicine and advanced clinical diagnostics

Making the Shift from Technological Innovation to Operational Excellence: Delivering on the Promise Of Next-Generation Sequencing for Personalized Medicine

Posted by Peter Duncan on Apr 22, 2019 9:44:00 AM

As originally seen in The Journal of Precision Medicine March 2019.

Targeted therapies and now recently, immunotherapies, have demonstrated great promise towards increasing response rates, as well as duration of response for cancer patients. This is often achieved by understanding biomarkers associated with therapeutic response and then stratifying patients accordingly.
Read More

Topics: NGS, Precision Medicine, next gen sequencing

The Full Authority Companion Diagnostic

Posted by Yves Konigshofer on Feb 21, 2019 12:30:00 PM

It is very likely that on your last flight the turbofan engines were controlled by full authority digital engine controls – FADECs for short. FADECs have played a significant role in keeping airline ticket prices low (except during holidays) by continually adjusting engine parameters so that the engine operates with maximum fuel efficiency and within operational limits, allowing pilots to focus on other tasks.

Read More

Topics: NGS, FDA, clinical genomics

Keys to Better Liquid Biopsy Assay Sensitivity – AMP Corporate Workshop Video

Posted by Sam Blier on Jan 24, 2019 10:30:00 AM

“So as everyone here is aware, I’m sure, detection of circulating tumor DNA is challenging. There’s very little of it, to start with.” Hardly a revolutionary statement by Tony Godfrey, PhD, (Associate Chair, Surgical Research and Associate Professor of Surgery, Boston University School of Medicine) but an important acknowledgement from a leading expert of the difficulty faced by laboratorians

Read More

Topics: NGS, ctDNA, Amp, NGS assays, liquid biopsy, NGS reference materials

Workshop Video: Two Experts Take on Clinical Genomics QC and Standardization at AMP

Posted by Sam Blier on Dec 18, 2018 4:45:00 PM

If you’ve attended the AMP Annual Meeting over the years or seen any of the headlines it generates, you know how next-generation sequencing-based assays are becoming indispensable diagnostic, prognostic, and predictive tools for a growing number of disease states. But just as important as the newest biomarker or latest chemistry – but seemingly less headline-worthy – are NGS quality control and standardization.

Read More

Topics: NGS, Amp, clinical genomics, iQ NGS

Keep Calm and Standardize On

A Panel of Experts Discusses Best Practices for Clinical NGS Quality Management in the Rapidly Evolving Field of Clinical Genomics

Posted by Peter Duncan on Oct 5, 2018 10:00:00 AM

There is that old adage that says the only thing that is constant is change. This is one of those universal truths we have all come to accept. Heck, even Dunkin' Donuts, widely credited as being the inventor of the word “Donut,” is dropping the word from their brand name. Blasphemy! But that is for another blog...

Read More

Topics: NGS, QC Challenges, QC Management Software, qc management

Developing a Rock-Solid Lung Cancer Assay, Part 2

Posted by Yves Konigshofer on Jul 2, 2018 4:45:00 PM

In a recent post, we discussed key considerations for designing a robust next-generation sequencing (NGS)-based lung cancer assay. Putting those plans into action in the development phase brings forth a new set of challenges. Through our experience developing NGS reference materials and the relationships we’ve built with assay developers of all stripes, we’ve identified those important factors and ways to navigate them. But before you begin designing and optimizing your assay, you should become very familiar with binomial and Poisson distributions and their use because the outcome of many analytical steps can be modeled and explained with them.

Read More

Topics: Cancer, NGS, NGS assays, assay development, NGS reference materials, Lung Cancer

What Is The Difference Between Quality Control Software Like iQ NGS And LIMS?

Posted by Lorn Davis on Apr 6, 2018 8:00:00 AM

SeraCare Life Sciences, in partnership with GenomeWeb, recently offered this exciting on-demand webinar: 

Read More

Topics: NGS, QC Challenges, assay performance, QC Management Software, Clinical NGS Assays, qc management

Developing a Rock-Solid Lung Cancer Assay

Posted by Yves Konigshofer on Mar 15, 2018 11:55:00 AM

Next-generation sequencing (NGS) allows deeper insights than ever before into the human genome and a host of diseases and conditions. So it makes sense that there is a worldwide movement to employ NGS in a growing number of applications. But as the saying goes, with great power comes great responsibility.



Read More

Topics: Cancer, NGS, NGS reference materials, Clinical NGS Assays, reference materials, Lung Cancer

Reliable Interpretation of NGS Data: New Poster Talk Video

Posted by Cynthia Hendrickson, CEO Directed Genomics on Feb 1, 2018 8:00:00 AM

The ability to rapidly and effectively evaluate the performance of customized next-generation sequencing (NGS) panels is critical to provide high-quality sequencing solutions to customers. New England Biolabs®, together with Directed Genomics®, is developing a new offering, NEBNext Direct® Custom Ready Panels, which will allow researchers to select from a large library of genes for which baits have been developed and optimized, thus enabling rapid deployment of customized target-enrichment panels. Directed Genomics has been collaborating with SeraCare Life Sciences in order to streamline the optimization and characterization of NEBNext Direct target enrichment panels. 

Read More

Topics: NGS, SeraSeq, Amp, NGS assays, Variant Allele Frequencies, NGS reference materials, reference materials

With so many options, how do you select the best NGS cancer assay?

Posted by Catherine Huang on Jan 11, 2018 12:10:00 PM

Clinical labs must constantly evolve their test offerings in order to support the most recent advances in clinical care. For next-generation sequencing (NGS) tumor profiling assays, there are often multiple commercially available kits with similar claims for gene content and sensitivity, as well as customized solutions. How can you quickly perform an effective evaluation of available assay systems to make a data-driven choice?

Read More

Topics: Cancer, NGS, next gen sequencing, fusion RNA, Clinical NGS Assays, reference materials